Over the course of three clinical trials, Aubagio 14 mg was found to be effective compared to a placebo in three key measures: relapses, brain lesions, and disability progression. Aubagio 7 mg was shown to be effective compared to a placebo in two of the three key measures: relapses and brain lesions. Over the course of the trials, Aubagio 14 mg was more effective than Aubagio 7 mg at reducing relapse rates, increasing the number of people who remained relapse-free, reducing new lesions, and reducing total lesion volume. You can read more about the clinical studies here: Aubagio website: Clinical Studies Despite the superior efficacy of Aubagio 14 mg, however, your doctor may prescribe Aubagio 7 mg depending on your personal circumstances. For example, if your disease is less severe the 7 mg dosage may have the desired therapeutic effect while reducing the risk of side effects such as hair thinning or loss, nausea, and diarrhea.